Clinical characteristics and outcomes of children with hypertensive encephalopathy
- PMID: 40676587
- PMCID: PMC12269113
- DOI: 10.1186/s12887-025-05909-w
Clinical characteristics and outcomes of children with hypertensive encephalopathy
Abstract
Background: Hypertensive encephalopathy (HE) is characterized by a severe increase in blood pressure, leading to neurological symptoms such as severe headache, seizure, and mental status change. Prompt medical treatment is crucial, often leading to full recovery without long-term neurological deficits. However, untreated cases can result in serious complications. This study aimed to describe the clinical characteristics and outcomes of children who developed HE.
Materials and methods: A retrospective review of medical records in patients aged < 18 years diagnosed with HE in Ramathibodi Hospital was conducted. Data were collected, including demographics, underlying conditions, clinical presentations, blood pressure levels during HE, medications used, diagnostic investigations, and outcomes. Patients with pre-existing neurological symptoms or incomplete data were excluded. Data between the groups with kidney diseases and non-kidney diseases were compared.
Results: Fifty-three patients (26 males) were included with a mean age of 8.9 ± 4 years and a median follow-up time of 47.8 months. Kidney disease (51%) was the most common cause of hypertension. Patients with kidney disease were older (10.3 vs. 7.5 years, p = 0.01), had a shorter duration between the diagnosis of underlying conditions and development of HE (70 vs. 457 days, p = 0.04), and a larger proportion of females (66.7% vs. 34.6%, p = 0.02). Neither clinical manifestations, such as generalized tonic-clonic seizures, headaches, and mental status changes, nor survival were different between the kidney and non-kidney groups. Five patients who developed recurrent episodes of HE had the underlying diseases involving endothelial injuries, such as small vessel vasculitis, and were on calcineurin inhibitors after hematopoietic stem cell transplantation (HSCT).
Conclusions: Patients with kidney diseases were older and developed HE earlier, but there was no difference in survival between the kidney and non-kidney groups. Recurrent episodes of HE were detected in patients with small vessel vasculitis or taking calcineurin inhibitors after HSCT, prompting the pediatricians to be vigilant for blood pressure control in these patients.
Keywords: Characteristics; Children; Hypertensive encephalopathy; Outcomes.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The present study was approved, and informed consent was waived by the Ethics Committee for Human Research, Faculty of Medicine Ramathibodi Hospital, Mahidol University (MURA 2023/373) due to the retrospective design of the present study. The present study adhered to the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Similar articles
-
Hypertensive Crisis.2025 Jun 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jun 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29939523 Free Books & Documents.
-
Branched-chain amino acids for people with hepatic encephalopathy.Cochrane Database Syst Rev. 2017 May 18;5(5):CD001939. doi: 10.1002/14651858.CD001939.pub4. Cochrane Database Syst Rev. 2017. PMID: 28518283 Free PMC article.
-
Branched-chain amino acids for people with hepatic encephalopathy.Cochrane Database Syst Rev. 2015 Sep 17;(9):CD001939. doi: 10.1002/14651858.CD001939.pub3. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2017 May 18;5:CD001939. doi: 10.1002/14651858.CD001939.pub4. PMID: 26377410 Updated.
-
Branched-chain amino acids for people with hepatic encephalopathy.Cochrane Database Syst Rev. 2015 Feb 25;(2):CD001939. doi: 10.1002/14651858.CD001939.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2015 Sep 17;(9):CD001939. doi: 10.1002/14651858.CD001939.pub3. PMID: 25715177 Updated.
-
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2. Cochrane Database Syst Rev. 2023. PMID: 37467180 Free PMC article.
References
-
- Seeman T, Hamdani G, Mitsnefes M. Hypertensive crisis in children and adolescents. Pediatr Nephrol. 2019;34(12):2523–37. - PubMed
-
- Sharma S, Tiwari S, Yadav T, Saini L, Mittal A, Khera D, Garg PK, Khera PS. Magnetic resonance imaging patterns and perfusion changes of posterior reversible encephalopathy syndrome in children with clinical outcome correlation. Pediatr Radiol. 2024;54(11):1884–95. - PubMed
-
- Halbach SM, Stein D. Posterior reversible encephalopathy syndrome in children and adolescents. Curr Hypertens Rep. 2024;26(8):349–54. - PubMed
-
- Hilal K, Khandwala K, Sajjad N, Kaleemi R, Malik AA, Mohsin S, Ibrahim SH. Paediatric posterior reversible encephalopathy syndrome: is there an association of blood pressure with imaging severity and atypical magnetic resonance characteristics? Pediatr Radiol. 2022;52(13):2610–9. - PubMed
LinkOut - more resources
Full Text Sources